Published in Pharma Law Weekly, November 29th, 2005
The patent "Cyanocobalamin Treatment in Allergic Disease," European Patent EP1128835, grants Cobalis extensive patent protection paving the way for marketing PreHistin throughout the European Union where an estimated 80 million people suffer from seasonal and perennial allergies, as well as a host of other atopic diseases such as atopic asthma, atopic migraine and dermatitis.
PreHistin is a sublingual...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.